{"preliminary_commentary":{"by_channel":{"youtube":5,"podcast":3,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03834961\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ADVL1823","nct_id":"NCT03834961","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=advl1823-nct03834961. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive larotrectinib PO or by NG or G-tube BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity, or complete surgical resection of tumor.","label":"Treatment (larotrectinib)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-07-25","type":"ESTIMATED"},"conditions":["Central Nervous System Neoplasm","Infantile Fibrosarcoma","Recurrent Acute Leukemia","Refractory Acute Leukemia","Solid Neoplasm"],"enrollment":{"count":33,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Larotrectinib Sulfate","otherNames":["ARRY 470 Sulfate","LOXO 101 Sulfate","LOXO-101 Sulfate","Vitrakvi"],"type":"DRUG"}],"last_update":"2025-12-02","lead_sponsor":"Children's Oncology Group","official_title":"Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) of Children With Infantile Fibrosarcoma (IFS) Treated With Neoadjuvant Larotrectinib Prior to Local Control","timeFrame":"Up to 5 years"}],"references":[{"citation":"Laetsch TW, Voss S, Ludwig K, Hall D, Barkauskas DA, DuBois SG, Ronan J, Rudzinski ER, Memken A, Robinson K, Sorger J, Reid JM, Bhatla T, Crompton BD, Church AJ, Fox E, Weigel BJ. Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). J Clin Oncol. 2025 Apr;43(10):1188-1197. doi: 10.1200/JCO-24-01854. Epub 2024 Dec 9.","pmid":"39652801","type":"DERIVED"}],"start_date":{"date":"2019-10-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia","url":"https://clinicaltrials.gov/study/NCT03834961"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/advl1823-nct03834961"}